Patient Information Leaflet: Information for the User
Isentress 25mgchewable tablets
Isentress 100mg chewable tablets
raltegravir
Read the entire leaflet carefully before you start taking this medicine, as it contains important information for you.
If you are the parent of a child taking Isentress, please read this information carefully with your child.
Contents of the Leaflet
What Isentress is
Isentress contains the active ingredient raltegravir. Isentress is an antiviral medicine that acts against the human immunodeficiency virus (HIV). This is the virus that causes acquired immune deficiency syndrome (AIDS).
How Isentress works
The virus produces an enzyme called HIV integrase, which helps the virus enter the body's cells and multiply. Isentress prevents this enzyme from working. When used with other medicines, Isentress can reduce the amount of HIV in the blood (this is called the "viral load") and increase the number of CD4 cells (a type of white blood cell that plays an important role in keeping the immune system healthy to help fight infection). By reducing the amount of HIV in the blood, it can improve the functioning of your immune system. This means your body can fight infection better.
When Isentress should be used
Isentress is used to treat patients infected with HIV. Your doctor has prescribed Isentress to help you control your HIV infection.
Do not take Isentress:
Warnings and precautions
Consult your doctor, pharmacist, or nurse before starting Isentress.
Remember that Isentress does not cure HIV infection. This means you can still get infections or other illnesses related to HIV. You should continue to see your doctor regularly while taking this medicine.
Mental health problems
Tell your doctor if you have a history of depression or mental illness. Depression, including suicidal thoughts and behaviors, has been seen in some patients taking this medicine, especially in patients with a history of depression or mental illness.
Bone problems
Some patients taking combination antiretroviral therapy may develop a bone disease called osteonecrosis (death of bone tissue caused by loss of blood supply to the bone). The duration of combination antiretroviral therapy, the use of corticosteroids, alcohol consumption, severe immune system suppression, increased body mass index, among others, may be some of the many risk factors for developing this disease. Signs of osteonecrosis are joint stiffness, discomfort, and pain (especially in the hip, knee, and shoulder) and difficulty moving. If you experience any of these symptoms, see your doctor.
Liver problems
Tell your doctor, pharmacist, or nurse if you have had liver problems in the past, including hepatitis B or C. Your doctor may assess the severity of your liver disease before deciding if you can take this medicine.
Infections
If you notice any symptoms of infection, such as fever and/or feeling unwell, tell your doctor, pharmacist, or nurse immediately. Some patients with advanced HIV infection who have previously had opportunistic infections may develop signs and symptoms of inflammation due to previous infections soon after starting HIV treatment. These symptoms are believed to be due to the improvement in the body's immune response, which allows the body to fight infections that may have been present but not showing obvious symptoms.
In addition to opportunistic infections, autoimmune disorders (a condition that occurs when the immune system attacks healthy body tissue) may also occur after you start taking medicines for your HIV infection. Autoimmune disorders may occur many months after starting treatment. If you notice any symptoms of infection or other symptoms such as muscle weakness, weakness starting in the hands and feet and moving up towards the trunk of the body, palpitations, tremors, or hyperactivity, tell your doctor immediately to receive necessary treatment.
Muscle problems
Contact your doctor, pharmacist, or nurse immediately if you notice unexplained muscle pain, tenderness, or muscle weakness while taking this medicine.
Skin problems
Contact your doctor immediately if you develop a rash. Serious and potentially life-threatening skin reactions and allergic reactions have been reported in some patients taking this medicine.
Other medicines and Isentress
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines, with or without a prescription.
Isentress may interact with other medicines.
Tell your doctor, pharmacist, or nurse if you are taking, have recently taken, or might take:
Taking Isentress with food and drinks
See section 3.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.
If you are pregnant or breastfeeding, consult your doctor, pharmacist, or nurse before using any medicine.
Driving and using machines
Do not operate machinery, drive, or ride a bicycle if you feel dizzy after taking this medicine.
Isentress 25 mg chewable tablet
Isentress 25mg chewable tablet contains fructose
This medicine contains up to 0.54 mg of fructose in each tablet.
Fructose may damage teeth.
Isentress 25mg chewable tablet contains sorbitol
This medicine contains up to 1.5 mg of sorbitol (E 420) in each tablet.
Isentress 25mg chewable tablet contains sucrose
This medicine contains up to 3.5 mg of sucrose in each 25 mg chewable tablet.
Sucrose may damage teeth.
If your doctor has told you that you have an intolerance to some sugars, consult with them before taking this medicine.
Isentress 25mg chewable tablet contains aspartame
This medicine contains up to 0.47 mg of aspartame (E 951) in each 25 mg chewable tablet, which is equivalent to up to 0.05 mg of phenylalanine. Aspartame is a source of phenylalanine, which may be harmful if you have phenylketonuria (PKU), a rare genetic disorder in which phenylalanine accumulates because the body cannot eliminate it properly.
Isentress 25mg chewable tablet contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; this is essentially "sodium-free".
Isentress 100 mg chewable tablet
Isentress 100mg chewable tablet contains fructose
This medicine contains up to 1.07 mg of fructose in each tablet.
Fructose may damage teeth.
Isentress 100mg chewable tablet contains sorbitol
This medicine contains up to 2.9 mg of sorbitol (E 420) in each tablet.
Isentress 100mg chewable tablet contains sucrose
This medicine contains up to 7 mg of sucrose in each 100 mg chewable tablet.
Sucrose may damage teeth.
If your doctor has told you that you have an intolerance to some sugars, consult with them before taking this medicine.
Isentress 100mg chewable tablet contains aspartame
This medicine contains up to 0.93 mg of aspartame (E 951) in each 100 mg chewable tablet, which is equivalent to up to 0.10 mg of phenylalanine. Aspartame is a source of phenylalanine, which may be harmful if you have phenylketonuria (PKU), a rare genetic disorder in which phenylalanine accumulates because the body cannot eliminate it properly.
Isentress 100mg chewable tablet contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; this is essentially "sodium-free".
Follow the instructions for taking this medicine exactly as your doctor, pharmacist, or nurse has told you. If you are unsure, ask your doctor, pharmacist, or nurse again. Isentress should be used in combination with other medicines for HIV infection.
The 100 mg chewable tablet can be divided into two equal halves. However, splitting tablets should be avoided whenever possible.
How much to take
Dose for children between 2 and 11years of age
Your doctor will recommend the appropriate dose of chewable tablets based on the child's age and weight. This dose should not exceed 300 mg twice a day. Your doctor will tell you how many chewable tablets the child should take.
Isentress is also available as a 400 mg tablet, a 600 mg tablet, and an oral suspension granule.
Do not switch between the chewable tablet, oral suspension granule, 600 mg tablet, or 400 mg tablet without consulting your doctor, pharmacist, or nurse first.
Children should attend scheduled visits with their doctor, as their Isentress dose may need to be adjusted as they get older, grow, or gain weight. Your doctor may also want to prescribe the 400 mg tablet when they are able to swallow a tablet.
This medicine can be taken with or without food or drinks.
If you take more Isentress than you should
Do not take more tablets than your doctor has recommended. If you take more tablets than recommended, consult your doctor.
If you forget to take Isentress
If you stop taking Isentress
It is important to take Isentress exactly as your doctor has told you. Do not change the dose or stop taking this medicine without consulting your doctor, pharmacist, or nurse first. Do not stop taking it, because:
If you have any further questions about the use of this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
Severe Adverse Effects– these are rare (may affect up to 1 in 100 people)
See a doctor immediately if you notice any of the following adverse effects:
See your doctor immediately if you notice any of the above-mentioned adverse effects.
Frequent: the following adverse effects may affect up to 1 in 10 people
Rare: the following adverse effects may affect up to 1 in 100 people
Other adverse effects in children and adolescents
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect that is not listed in this leaflet. You can also report them directly through the national reporting system included in Appendix V. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of the packaging and any unused medicine. This will help protect the environment.
Isentress Composition
The active ingredient is raltegravir.
25 mg chewable tablets:
Each chewable tablet contains 25 mg of raltegravir (potassium salt).
The other ingredients are: hydroxypropylcellulose, sucralose, sodium saccharin, sodium citrate dihydrate, mannitol (E 421), yellow iron oxide, monoammonium glycyrrhizinate, sorbitol (E 420), fructose, natural and artificial flavors (orange, banana, and masking), aspartame (E 951), sucrose, crospovidone Type A, magnesium stearate, sodium stearyl fumarate, ethylcellulose 20 cP, ammonium hydroxide, medium-chain triglycerides, oleic acid, hypromellose 2910/6cP, and macrogol/PEG 400.
100 mg chewable tablets:
Each chewable tablet contains 100 mg of raltegravir (potassium salt).
The other ingredients are: hydroxypropylcellulose, sucralose, sodium saccharin, sodium citrate dihydrate, mannitol (E 421), red iron oxide, yellow iron oxide, monoammonium glycyrrhizinate, sorbitol (E 420), fructose, natural and artificial flavors (orange, banana, and masking), aspartame (E 951), sucrose, crospovidone Type A, magnesium stearate, sodium stearyl fumarate, ethylcellulose 20 cP, ammonium hydroxide, medium-chain triglycerides, oleic acid, hypromellose 2910/6cP, and macrogol/PEG 400.
Product Appearance and Package Contents
Isentress 25 mg chewable tablets:
Light yellow chewable tablet, with orange and banana flavor, round, with the MSD corporate logo on one side and "473" on the other side.
One pack size is available: 1 bottle with 60 tablets. The bottle contains a desiccant.
Isentress 100 mg chewable tablets:
Light orange chewable tablet, with orange and banana flavor, oval, scored on both sides, engraved on one side with the MSD corporate logo and the inscription "477" and without inscription on the other side.
One pack size is available: 1 bottle with 60 tablets. The bottle contains a desiccant.
Marketing Authorization Holder and Manufacturer
Merck Sharp & Dohme B.V.
Waarderweg 39
2031 BN Haarlem
Netherlands
You can request more information about this medicine by contacting the local representative of the marketing authorization holder:
Belgium/Belgique/Belgien MSD Belgium Tel: +32(0)27766211 dpoc_belux@msd.com | Lithuania UAB Merck Sharp & Dohme Tel: +370 5 2780 247 dpoc_lithuania@msd.com |
Luxembourg/Luxemburg MSD Belgium Tel: +32(0)27766211 dpoc_belux@msd.com | |
Czech Republic Merck Sharp & Dohme s.r.o. Tel: +420 233 010 111 dpoc_czechslovak@merck.com | Hungary MSD Pharma Hungary Kft. Tel: +36 1 888 5300 hungary_msd@merck.com |
Denmark MSD Danmark ApS Tel: +45 4482 4000 dkmail@msd.com | Malta Merck Sharp & Dohme Cyprus Limited Tel: 8007 4433 (+356 99917558) malta_info@merck.com |
Germany MSD Sharp & Dohme GmbH Tel: +49 (0) 89 20 300 4500 medinfo@msd.de | Netherlands Merck Sharp & Dohme B.V. Tel: 0800 9999000 (+31 23 5153153) medicalinfo.nl@merck.com |
Estonia Merck Sharp & Dohme OÜ Tel: +372 614 4200 dpoc.estonia@msd.com | Norway MSD (Norge) AS Tel: +47 32 20 73 00 medinfo.norway@msd.com |
Greece MSD Α.Φ.Ε.Ε. Tel: +30 210 98 97 300 dpoc_greece@merck.com | Austria Merck Sharp & Dohme Ges.m.b.H. Tel: +43 (0) 1 26 044 dpoc_austria@merck.com |
Spain Merck Sharp & Dohme de España, S.A. Tel: +34 91 321 06 00 msd_info@msd.com | Poland MSD Polska Sp. z o.o. Tel: +48 22 549 51 00 msdpolska@merck.com |
France MSD France Tel: +33 (0) 1 80 46 40 40 | Portugal Merck Sharp & Dohme, Lda Tel: +351 21 4465700 inform_pt@merck.com |
Croatia Merck Sharp & Dohme d.o.o. Tel: + 385 1 6611 333 croatia_info@merck.com | Romania Merck Sharp & Dohme Romania S.R.L. Tel: +40 21 529 29 00 msdromania@merck.com |
Ireland Merck Sharp & Dohme Ireland (Human Health) Limited Tel: +353 (0)1 2998700 medinfo_ireland@msd.com | Slovenia Merck Sharp & Dohme, inovativna zdravila d.o.o. Tel: +386 1 520 4201 msd.slovenia@merck.com |
Iceland Vistor ehf. Tel: + 354 535 7000 | Slovak Republic Merck Sharp & Dohme, s. r. o. Tel: +421 2 58282010 dpoc_czechslovak@merck.com |
Italy MSD Italia S.r.l. Tel: 800 23 99 89 (+39 06 361911) dpoc.italy@msd.com | Finland MSD Finland Oy Tel: +358 (0)9 804 650 info@msd.fi |
Cyprus Merck Sharp & Dohme Cyprus Limited Tel: 800 00 673 (+357 22866700) cyprus_info@merck.com | Sweden Merck Sharp & Dohme (Sweden) AB Tel: +46 77 5700488 medicinskinfo@msd.com |
Latvia SIA Merck Sharp & Dohme Latvija Tel: + 371 67025300 dpoc.latvia@msd.com |
Date of Last Revision of this Leaflet:<{MM/AAAA}><{month YYYY}>.
Detailed information on this medicine is available on the European Medicines Agency website: https://www.ema.europa.eu.